Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Technology developed to diagnose risk of early-stage breast cancer recurrence
February 17th, 2005
Sysmex Corporation, headquartered in Kobe, Japan, announced the development of a new technology based on a cell cycle profiling (C2P) for diagnosis of the risk of recurrence in patients with early-stage cancer. In a clinical study of about 200 cases conducted in collaboration with Shinzaburo Noguchi, Graduate School of Medicine, Osaka University, this technology was found to be a high degree of clinical usefulness in patients with early stages of breast cancer. This technology in combination with the conventional pathology makes it possible to accurately diagnose the risk of recurrence in patients of early-stage of breast cancer, thereby improving...
Source: Women's Health Weekly (2005-02-17)
|
